





Item 8.01

Other Events.

On April 18, 2018, the China Food and Drug Administration (CFDA) Center for Drug Development (CDE) posted on its website acceptance of the Investigative New Drug (IND) application for chimeric antigen receptor T cells (CAR-T) cancer therapies in treating patients with B-cell non-Hodgkin lymphoma (NHL) submitted by Cellular Biomedicine Group (Shanghai) Ltd. and Shanghai Cellular Biopharmaceutical Group Ltd., two of our wholly-owned subsidiaries of Cellular Biomedicine Group, Inc. (collectively, the Company). There can be no assurance that the application will ultimately be approved.

In December 2017, the Chinese government issued clinical trial guidelines concerning development and testing of cell therapy products, including immune cell therapies such as CAR-T cell therapeutics. The Company currently has ongoing CAR-T Phase I clinical trials in China; CARD-1 for NHL and Diffuse Large B-cell Lymphoma (DLBCL), and CALL-1 for adult Acute Lymphoblastic Leukemia (ALL).



SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Cellular Biomedicine Group,  
Inc.

Date: April 19, 2018 By: /s/ Bizuo (Tony) Liu  
Bizuo (Tony) Liu  
Chief Executive Officer